STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Overall, 262 patients with ER+/HER2– ...

Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (ESR1 ...

Imlunestrant, alone or with Verzenios, improved patient-reported outcomes in ER-positive, HER2-negative advanced breast cancer post-endocrine therapy. In patients with an ESR1 mutation, imlunestrant ...

Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Imlunestrant monotherapy significantly improved PFS compared with standard endocrine therapy, with a median PFS of 5.5 months vs 3.8 months. The combination of imlunestrant and abemaciclib further ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus ...